PAA 2022 , Human Trials , Covid , MND , Oncology , HVTL-1, K9 Phase III, page-914

I enjoyed your Post QQ
You may wish to look at BIT on the 2nd of May to see what positive mouse trial data can bring in the way of Value and open the door for progress.
Then 30 days later FDA approval for their clinical covid program.


No Human Cancer Trial scheduled due to ASX Regulation ruling you must have 2 Q operating Capital and if you announce any trials that exceed your cash holding you must Announce how you will raise the funds to Trial..

IMHO had the Company had a clue at Messaging we would be sitting in the high 20c 30c mark circa $100m

Here is my question to you
Why is PAA only valued at $25m? The next Phase II Oncology Company is $100m plus
Why is it taking longer to commercialise a Repurposed drug than a New drug?

Finally , Why didn't PAA announce a Phase II Covid Trial ? and only mention it on line 4 of the MND trial..

As you know cash position will be critical and the Company clearly has no intention to message the wider Investment Community, eg not a single announcement for July...

Here's is Mollard 2 years ago June 2020,his words not mine QQ... I'm not the one letting you down mate.


PAA is just kicking the can down the road QQ..... Best of Luck with your Investments NZT